Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | BCR | P11274 | 1/20 | 0.35 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.34 |
| ▸ | STK17B | O94768 | 1/20 | 0.34 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29464288 | 1.00 | KMT2A (0.46) | KMT2AMEN1IGF1RALDH1A1L3MBTL1 | |
| SCHEMBL3139282 | 0.81 | KMT2A (0.49) | KMT2AMEN1IGF1RALDH1A1L3MBTL1 | |
| SCHEMBL13194676 | 0.80 | KMT2A (0.46) | KMT2AMEN1IGF1RALDH1A1L3MBTL1 | |
| SCHEMBL23029862 | 0.78 | CSNK1A1 (0.38) | KMT2AMEN1ALDH1A1L3MBTL1CSNK1A1 | |
| SCHEMBL23759601 | 0.77 | MEN1 (0.43) | KMT2AMEN1IGF1RALDH1A1L3MBTL1 | |
| SCHEMBL5151737 | 0.77 | STK17A (0.50) | KMT2AMEN1ALDH1A1L3MBTL1STK17B | |
| SCHEMBL30989056 | 0.77 | ALDH1A1 (0.35) | KMT2AMEN1ALDH1A1L3MBTL1CSNK1A1 | |
| SCHEMBL24533739 | 0.77 | NUDT1 (0.36) | KMT2AMEN1ALDH1A1L3MBTL1CSNK1A1 | |
| SCHEMBL21287682 | 0.77 | ALDH1A1 (0.35) | KMT2AMEN1ALDH1A1L3MBTL1CSNK1A1 | |
| SCHEMBL25695712 | 0.77 | ALDH1A1 (0.54) | KMT2AMEN1IGF1RALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552796-B2 | EED inhibitor, and preparation method therefor and use thereof | JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) | 2026-02-17 | — | — | US | disclosed |
| EP-4056570-B1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | UNIV SHANGHAI TECHNOLOGY (CN) | 2026-01-07 | — | — | EP | disclosed |
| US-20230028221-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| US-20230028221-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| US-20230002414-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| EP-4056570-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ShanghaiTech University (CN) | 2022-09-14 | — | — | EP | disclosed |
| EP-4019521-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | Blueray Therapeutics (Shanghai) Co., Ltd (CN) | 2022-06-29 | — | — | EP | disclosed |
| US-20220073521-A1 | PYRIMIDINE AND FIVE-MEMBERED NITROGEN HETEROCYCLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | TUOJIE BIOTECH (SHANGHAI) CO., LTD. (CN) | 2022-03-10 | — | — | US | disclosed |
| EP-3889153-A1 | PYRIMIDINE AND FIVE-MEMBERED NITROGEN HETEROCYCLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | Tuojie Biotech (Shanghai) Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
| WO-2021083380-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海科技大学 | 2021-05-06 | — | — | WO | disclosed |
| EP-2545058-B1 | TETRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS INHIBITORS OF HISTAMINE RECEPTORS | KALYPSYS INC (US) | 2016-08-24 | — | — | EP | disclosed |
| US-8569300-B2 | Substituted tetrazolo[1,5-A]pyrazine inhibitors of histamine receptors for the treatment of disease | KALYPSYS INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569300-B2 | Substituted tetrazolo[1,5-A]pyrazine inhibitors of histamine receptors for the treatment of disease | KALYPSYS INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569300-B2 | Substituted tetrazolo[1,5-A]pyrazine inhibitors of histamine receptors for the treatment of disease | KALYPSYS INC. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2545058-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | Kalypsys, Inc. (US) | 2013-01-16 | — | — | EP | disclosed |
| CN-102869666-A | Heterocyclic inhibitors of histamine receptors for the treatment of disease | KALYPSYS INC | 2013-01-09 | — | — | CN | disclosed |
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| WO-2011112766-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002414-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | EZH2, EED, SUZ12 | KMT2A 85/4885MEN1 3700/4885IGF1R 4267/4885 |
| US-12552796-B2 | EED inhibitor, and preparation method therefor and use thereof | HSD11B1, CYP4A11, CYP8B1 | KMT2A 3880/4885MEN1 1206/4885IGF1R 4484/4885 |
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | KMT2A 665/4885MEN1 1013/4885IGF1R 1419/4885 |
| US-20220073521-A1 | PYRIMIDINE AND FIVE-MEMBERED NITROGEN HETEROCYCLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | PTPN5, PTPN11, PTPN1 | KMT2A 2582/4885MEN1 1387/4885IGF1R 1515/4885 |
| US-20230028221-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP4F11, CYP4A11, HSD11B1 | KMT2A 3987/4885MEN1 954/4885IGF1R 4420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.